These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. Finley SD; Popel AS AAPS J; 2012 Sep; 14(3):500-9. PubMed ID: 22547351 [TBL] [Abstract][Full Text] [Related]
27. The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Neufeld G; Kessler O; Herzog Y Adv Exp Med Biol; 2002; 515():81-90. PubMed ID: 12613545 [TBL] [Abstract][Full Text] [Related]
28. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Castro-Rivera E; Ran S; Thorpe P; Minna JD Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11432-7. PubMed ID: 15273288 [TBL] [Abstract][Full Text] [Related]
29. Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment. Gaddy TD; Wu Q; Arnheim AD; Finley SD PLoS Comput Biol; 2017 Dec; 13(12):e1005874. PubMed ID: 29267273 [TBL] [Abstract][Full Text] [Related]
31. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Man XY; Yang XH; Cai SQ; Yao YG; Zheng M Mol Med; 2006; 12(7-8):127-36. PubMed ID: 17088944 [TBL] [Abstract][Full Text] [Related]
32. Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Wu FTH; Stefanini MO; Gabhann FM; Popel AS Methods Enzymol; 2009; 467():461-497. PubMed ID: 19897104 [TBL] [Abstract][Full Text] [Related]
33. Complex receptor-ligand dynamics control the response of the VEGF system to protease injury. Forsten-Williams K; Kurtagic E; Nugent MA BMC Syst Biol; 2011 Oct; 5():170. PubMed ID: 22014244 [TBL] [Abstract][Full Text] [Related]
34. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702 [TBL] [Abstract][Full Text] [Related]
35. Molecular controls of lymphatic VEGFR3 signaling. Deng Y; Zhang X; Simons M Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775 [TBL] [Abstract][Full Text] [Related]
37. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832 [TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303 [TBL] [Abstract][Full Text] [Related]